Drug Research
University team uses AI to decode asbestos-linked cancer
Researchers at the University of Leicester have used artificial intelligence (AI) to gain new insights into mesothelioma, a cancer caused by breathing asbestos particles that typically occurs in the linings of the lungs or abdomen.
The Leicester Mesothelioma Research Programme...
Drug Research
Moderna Announces New Supply Agreement with the Philippines for 7 Million Additional Doses of COVID-19 Vaccine Moderna
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Philippines has secured 7 million additional doses of COVID-19 Vaccine Moderna through a new supply agreement, bringing its confirmed order commitment up to 20...
Drug Research
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Evotec SE announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to...
Drug Research
RDIF and Virchow Biotech partner for production of Sputnik V vaccine in India
The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Virchow Biotech Private Limited (part of the Virchow Group), one of the leading vaccine and pharmaceutical producers in India, announce the agreement to produce in the country up...
Drug Research
Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK
Boston Pharmaceuticals announced a pioneering three-year out-license and option agreement with GlaxoSmithKline PLC. Boston Pharmaceuticals will become a preferred GSK partner for select pre-phase 2 programs. This new agreement builds on the relationship established in 2018 with Boston Pharmaceuticals’...
Drug Research
US FDA approves Janssen’s PONVORY for relapsing multiple sclerosis
The US FDA has approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s (JNJ) PONVORY (ponesimod) for treating adults with relapsing forms of multiple sclerosis (MS).
PONVORY is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator. The approval will...
Drug Research
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH).
The companies will conduct a Phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy of Novo Nordisk’s semaglutide,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
